Can healthcare advertising break onto the Cannes ad festival main stage?
12 July 2016
Rumblings from healthcare agency executives and marketers about the separation of the Lions Health Festival from the full Cannes Lions International Festival of Creativity were reported inAdvertising Age's final analysis of the event. It noted the "grousing by agency, client and media executives alike" and named WebMD CEO David Schlanger as one of the executives who "believes it's time to more fully integrate health into the main show."
Business as usual for now, but post-Brexit funding, R&D worries remain at forefront
11 July 2016
One week on, and researchers in the U.K. still reeling from the Brexit vote have been told by the science minister Jo Johnson to carry on as before. In legal terms, nothing has changed. "We remain an EU member during the two-year negotiation period, with all rights and obligations that derive from this," Johnson said in a speech given at the headquarters of research charity the Wellcome Trust, to an audience including university vice chancellors, representatives of research funding bodies and practicing scientists.
Where should the EMA move to? That’s not up to us, regulator says
11 July 2016
Confidentially, EMA head Guido Rasi has said that a move from the U.K. to leave the EU was “a nightmare with immediate consequences,” although publicly the regulator has been keen to dampen concerns from behind a wall of silence.
Transparency is the goal as Europe goes live on payment disclosure
11 July 2016
Websites publishing details of payments from pharma companies to health care professionals have gone live as Europe presses the button on its version of the U.S. Sunshine Act, and makes information on money paid to individuals available for public scrutiny for the first time.
Medical school hasn’t changed much in a century. Here are 5 ways to fix that
11 July 2016
Like many aspects of health care, medical education evolves slowly. The modern curriculum is based on the Flexner Report — a review published in 1910. It hasn’t changed much since then.
Scientists discover new threat to antibiotic of last resort
08 July 2016
European scientists have discovered another gene that makes bacteria resistant to the antibiotic of last resort, one that could spread more easily among other kinds of bacteria.
VC funding down YOY in 1H: Just fewer late-stage players?
08 July 2016
In the first quarter of 2016, private U.S. biopharmas tracked by BioWorld Snapshots raised about $380 million less than the same quarter in 2015, but the year-over-year decline was easy to shrug off because the first quarter of 2015 contained a monster $450 million series C round by Cambridge, Mass.-based Moderna Therapeutics Inc. "Call it up 4.7 percent on an adjusted basis," I quipped at the time.
U.S. activity for biotech IPOs picks up in the second quarter
08 July 2016
After a slow start to the year, IPO activity for biotech companies picked up with 11 graduating to the public arena. However, the total amount raised was lower than the first quarter haul with most companies in the second quarter pricing their offerings within or below their ranges, and precious few transactions generated enough support to push above their original expectations reflecting the fact that the financial markets still remain volatile.
EyewireTV – FDA Approves Raindrop Inlay; Humira for Uveitis Treatment
08 July 2016
In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.
Drug industry CEOs lead new task force on Brexit's pharma fallout
08 July 2016
Drug industry and government officials have set up a task force to address regulatory and other problems facing the pharmaceutical sector following Britain's decision to leave the European Union.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024